MFGE8 and breast cancer: To assess whether sEV-MDA231 promotes tumorigenic or metastatic changes in other BC recipient cells, and to evaluate the role/contribution of lactadherin present in sEV-MDA231, non-metastatic MCF7, T47D, or ZR75, and non-tumorigenic MCF10A cells were incubated with sEV-MDA231 cells that were previously treated with a blocking monoclonal antibody against lactadherin, and the migratory capacity of the recipient cells was evaluated.